RXRX (STOCKS)
Recursion Pharmaceuticals, Inc. Class A Common Stock
$3.540000
+0.120000 (+3.51%)
Prev close: $3.420000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Najat Khan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,867.55M
- Employees
- 800
- P/E (TTM)
- -2.31
- P/B (TTM)
- 1.60
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
6
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.21 | $-0.32 | +0.1120 | +34.78% |
|
Sep 2025 (Q3)
|
$-0.36 | $-0.38 | +0.0174 | +4.61% |
|
Jun 2025 (Q2)
|
$-0.41 | $-0.36 | -0.0530 | -14.85% |
|
Mar 2025 (Q1)
|
$-0.50 | $-0.54 | +0.0355 | +6.63% |
Financial Statements
| Revenues | $74.68M |
| Benefits Costs and Expenses | $719.58M |
| Cost Of Revenue | $70.95M |
| Costs And Expenses | $722.81M |
| Gross Profit | $3.73M |
| Nonoperating Income/Loss | $3.24M |
| Operating Expenses | $651.86M |
| Research and Development | $475.27M |
| Other Operating Expenses | $176.59M |
| Operating Income/Loss | -$648.13M |
| Income/Loss From Continuing Operations After Tax | -$644.76M |
| Income/Loss From Continuing Operations Before Tax | -$644.90M |
| Income Tax Expense/Benefit | -$136.00K |
| Income Tax Expense/Benefit, Current | $232.00K |
| Income Tax Expense/Benefit, Deferred | -$368.00K |
| Net Income/Loss | -$644.76M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$644.76M |
| Net Income/Loss Available To Common Stockholders, Basic | -$644.76M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.44 |
| Diluted Earnings Per Share | -$1.44 |
| Basic Average Shares | 447,446,109 |
| Diluted Average Shares | 447,446,109 |
| Assets | $1.47B |
| Current Assets | $812.85M |
| Prepaid Expenses | $11.74M |
| Other Current Assets | $801.10M |
| Noncurrent Assets | $661.29M |
| Fixed Assets | $103.93M |
| Intangible Assets | $309.90M |
| Other Non-current Assets | $247.45M |
| Liabilities | $343.27M |
| Current Liabilities | $147.71M |
| Accounts Payable | $18.12M |
| Wages | $31.77M |
| Other Current Liabilities | $97.82M |
| Noncurrent Liabilities | $195.56M |
| Equity | $1.13B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.13B |
| Liabilities And Equity | $1.47B |
| Net Cash Flow From Operating Activities | -$371.81M |
| Net Cash Flow From Operating Activities, Continuing | -$371.81M |
| Net Cash Flow From Investing Activities | -$16.87M |
| Net Cash Flow From Investing Activities, Continuing | -$16.87M |
| Net Cash Flow From Financing Activities | $521.53M |
| Net Cash Flow From Financing Activities, Continuing | $521.53M |
| Exchange Gains/Losses | $18.04M |
| Net Cash Flow | $150.90M |
| Net Cash Flow, Continuing | $132.85M |
| Comprehensive Income/Loss | -$600.41M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$600.41M |
| Other Comprehensive Income/Loss | -$600.41M |
| Other Comprehensive Income/Loss Attributable To Parent | $44.35M |